Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000552177 | SCV000656933 | uncertain significance | Pancreatic adenocarcinoma | 2020-02-05 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals with PALLD-related disease. This variant is present in population databases (rs151071844, ExAC 0.03%), and has an allele count higher than expected for a pathogenic variant (PMID: 28166811). This sequence change replaces arginine with cysteine at codon 490 of the PALLD protein (p.Arg490Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. |
Ambry Genetics | RCV004837767 | SCV005463962 | uncertain significance | not specified | 2024-10-08 | criteria provided, single submitter | clinical testing | The c.1468C>T (p.R490C) alteration is located in exon 9 (coding exon 8) of the PALLD gene. This alteration results from a C to T substitution at nucleotide position 1468, causing the arginine (R) at amino acid position 490 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |